title: Skin tumorigenic potential of benzanthrone: prevention by ascorbic acid.
abstract: Benzanthrone (BA) exposed occupational workers have been found to exhibit toxicological manifestations in the skin, thus it is quite likely that long term exposure may lead to skin tumorigenicity. Thus, attempts were made to elucidate the tumor initiating and promoting potentials of pure (PBA) and commercial benzanthrone (CBA). Additionally, the preventive role of ascorbic acid (AsA) was also assessed. PBA showed tumor initiating activity while CBA demonstrated tumor initiating as well as promoting activities in two-stage mouse skin tumor protocol. Further, prior treatment of AsA to PBA and CBA followed by twice weekly application of 12-o-tetradecanoyl phorbal myristate acetate (TPA) resulted into delayed onset of tumor formation and similarly single application of 7,12-dimethylbenz [α] anthracene (DMBA) followed by twice weekly application of AsA and CBA showed an increase in the latency period. Thus, AsA showed a protective effect against CBA promoted skin tumor. Furthermore, the topical application of CBA significantly increased the levels of xenobiotic enzymes. The animals topically treated with AsA along with topical application of CBA, restored all the impairment observed in enzyme activities. Thus, this study suggested that AsA can be useful in preventing PBA and CBA induced skin tumorigenicity.
authors.affiliation: Food, Drug and Chemical Toxicology Group, CSIR-Indian Institute of Toxicology Research, (CSIR-IITR), Lucknow 226001, India. ndwivedi@sify.com
authors.forename: Neelam
authors.initials: N
authors.lastname: Dwivedi
authors.forename: Sandeep
authors.initials: S
authors.lastname: Kumar
authors.forename: Kausar M
authors.initials: KM
authors.lastname: Ansari
authors.forename: S K
authors.initials: SK
authors.lastname: Khanna
authors.forename: Mukul
authors.initials: M
authors.lastname: Das
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D001551:Benz(a)Anthracenes / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000633:toxicity; D002273:Carcinogens / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000633:toxicity; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D015536:Down-Regulation / Q000187:drug effects; D004790:Enzyme Induction / Q000187:drug effects; D005260:Female; D005982:Glutathione Transferase / Q000037:antagonists & inhibitors / Q000378:metabolism; D051379:Mice; D009363:Neoplasm Proteins / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D011808:Quinone Reductases / Q000096:biosynthesis / Q000737:chemistry / Q000378:metabolism; D012867:Skin / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D012878:Skin Neoplasms / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D013997:Time Factors
chemical_list: D016588:Anticarcinogenic Agents; D000975:Antioxidants; D001551:Benz(a)Anthracenes; D002273:Carcinogens; D065607:Cytochrome P-450 Enzyme Inhibitors; D009363:Neoplasm Proteins; D003577:Cytochrome P-450 Enzyme System; D011808:Quinone Reductases; D005982:Glutathione Transferase; C012768:benzanthrone; D001205:Ascorbic Acid
keywords: Ascorbic acid; Benzanthrone; Skin allergy; Skin tumor; Tumorigenic potential